In the past, FDA has made a point that comments posted by individuals (in an individual capacity and not on behalf of an organization, corporation, or other entity) are not posted publicly. This is a practice that has applied only to comments from individual consumers (comments from organizations, etc. are posted publically and displayed on regulations.gov).
Starting on October 15, 2015, FDA is set to change this policy and will begin posting all comments publicly. This practice, that was implemented to ensure “that the submitted comment does not include confidential information that the commenter or third party may not wish to be posted,” is being changed by the Agency in an attempt to increase transparency and promote the sharing of information.
In addition to the comments, FDA will be posting “any attachments submitted electronically, along with the State/Province and country (if provided), the name of the commenter’s representative (if any), and the category selected to identify the commenter (e.g., individual, consumer, academic, industry).” As such, the Agency warns against including confidential information that the commenter does not want posted publicly; examples of such information include: private medical information, social security number(s), or confidential business information (i.e. a manufacturing process).
For more information on the change, view the full notice here.
Your Business has Complex Challenges. ProPharma Group has Exceptional Solutions.
We partner with pharmaceutical, biotechnology, and medical device clients to tackle complex challenges. Contact us to learn how our experienced team can help ensure regulatory and development success throughout the product lifecycle.
Interested in gaining an industry edge? Let us help you stay up to date.
Gain an Industry Edge With Expertise From ProPharma Group
Get the latest insights and top tips from our experts, delivered right to your inbox.
Have a complex challenge?